Incidence, mortality and determinants of survival from cervical cancer in Northwest Russia: a registry-based cohort study

Grjibovski, Andrej M.; Дубовиченко, Д. М.; Saduakassova, Shynar; Zhatkanbayeva, Gulmira; Омарова, Г.К.; Shalgumbayeva, Gulnar; Valkova, L. E.; Valkov, Mikhail

doi:10.1093/inthealth/ihx068

Cited by 12 publications

(13 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients who presented with advanced stage died more than those with early stage. This result is in line with the studies conducted in New Zealand [ 33 , 34 ]. The increment of mortality could be as the cancer stage getting advanced, its metastasis rate could be increased and these factors might decrease the probability to respond a treatment and lead to death [ 35 ].…”

Section: Discussionsupporting

confidence: 92%

Determinants of Mortality among Cervical Cancer Patients Attending in Tikur Anbessa Specialized Hospital, Ethiopia: Institutional-Based Retrospective Study

Wassie

Fentie

Asefa

2021

Journal of Oncology

View full text Add to dashboard Cite

Background. Globally, about 570,000 cases and 311,000 deaths of cervical cancer occurred in 2018. It was the leading cause of cancer-related deaths among women in Africa. The global mean age at death of cervical cancer was about 59 years. This study aimed to assess the determinants of cervical cancer mortality among cervical cancer patients attending in Tikur Anbessa Specialized Hospital (TASH). Methods. Institutional-based retrospective cohort study was conducted in the oncology center of TASH, Ethiopia, from March to April 2019. Data were extracted from patients’ chart using structured checklist and analyzed using Stata 14.2. Cox regression was used to identify variables that affect the outcome variable. Result. From the total of 2045 reviewed medical records of cervical cancer patients, 1057 medical records were found to be complete and included in this study. The incidence of mortality among cervical cancer patients was 15.6/100/years. Mortality was significantly increased with advanced age (adjusted hazard ratio (AHR) = 1.02, 95% CI (1.01–1.03)), comorbidity (AHR = 1.8, 95% CI (1.39–1.89)), being anemic (AHR = 1.42, 95% CI (1.07–1.89)), advanced stage (AHR = 1.63, 95% CI (1.24–2.13)), and being substance user (AHR = 2.71, 95% CI (2.08–3.53)). Conclusion. The study revealed that the incidence of mortality within the cohort was 15.6/100/years. Mortality was significantly increased with advanced age, anemia, advanced stage, comorbidity, and using substances. It is better to give special attention to patients with anemia, advanced age, advanced stage, comorbidity, and substance usage. In addition, expanding cervical cancer early screening will decrease the mortality of patients.

show abstract

Section: Discussionsupporting

confidence: 92%

Determinants of Mortality among Cervical Cancer Patients Attending in Tikur Anbessa Specialized Hospital, Ethiopia: Institutional-Based Retrospective Study

Wassie

Fentie

Asefa

2021

Journal of Oncology

View full text Add to dashboard Cite

show abstract

“…Women with FIGO stage IV and III were about 12 and 7.4 times at high risk to die as compared to those with early clinical stage I respectively. This finding is in line with the studies conducted at north west Russia (HR = 3.8, 95% CI 2.5 to 5.8) [18], Nigeria (HR = 3.3, 95% CI: 1.2–8.9) [26], Ethiopia (HR = 2.60 (95%CI: 1.67–4.04) [23] and North East India (HR =1.8,95% CI:1.2 to 2.7) [20]. The similarity of these findings may be due to the reason that as the cancer stage increases, metastasis will also increase, which leads to compromising of patient’s immunity to resist other infections, difficulty of treating such complicated metastasis cases and these factors in aggregate increases the probability of dying [13].…”

Section: Discussionsupporting

confidence: 92%

“…The current study demonstrated that, about 38.6% cervical cancer patients could survive at least 5 years after diagnosis of cervical cancer. This is significantly lower than the researches conducted in Brazil which were 84% [14], India 62% [15], Malaysia 71.1% [16],China 66.61% [17],Northwest Russia 60.0% [18],Mysuru (India) 48.1% [19], but in line with the study conducted in North East India 40.7% [20].…”

Section: Discussionsupporting

confidence: 65%

Survival status and associated factors of death among cervical cancer patients attending at Tikur Anbesa Specialized Hospital, Addis Ababa, Ethiopia: a retrospective cohort study

et al. 2019

View full text Add to dashboard Cite

BackgroundCervical cancer is a cancer of uterine cervix caused mostly by sexually-acquired infection called Human papillomavirus (HPV. In developing region of the globe, fewer than 50% of women with cervical malignancy survive more than 5 years. Therefore, the objective of this study was to assess survival status and associated factors of death among cervical cancer patients attending at Tikur Anbesa Specialized Hospital (TASH), Ethiopia.MethodsFacility based retrospective cohort study was conducted from March to April 2019 at Tikur Anbesa Specialized Hospital oncology center. Data was collected from patient’s chart using pre-tested and structured checklist prepared in English and analyzed using STATA14.2. Cox regression model was used to identify Variables that affected survival.ResultThe overall survival rate was 38.62% at 5 years. There were a significance differences in survival experience between categories of stage of cervical cancer, age of patients, comorbidity, substance use, base line anemia and treatment modalities. Being stage IV [AHR = 11.76; 95% CI (4.02–34.4)],being advanced age [AHR = 5.99; 95% CI (2.1–17.08)], being comorbid [AHR = 1.58; 95%CI(1.14–2.19)], using substance [AHR = 1.56;95% CI(1.09–2.22)] and being anemic [AHR = 1.6;95% CI(1.11–2.36)] increased the risk of death.ConclusionThe overall survival rate was lower than high- and middle-income countries and Significant factors of death after diagnosis of cervical cancer were; advanced FIGO stage, base line anemia, comorbidity, substance use, advanced age and treatment modality. Authors recommend that it is better to expand cervical cancer early screening programs and treatment facilities, strengthen awareness in collaboration with public medias about cervical cancer prevention, screening and treatment options.

show abstract

“…This can be explained by the limited cervical cancer early diagnosis practices and lack of awareness campaigns for Tanzanian women in preventing the occurrence of cervical cancer [ 6 – 10 ]. These challenges could be responsible for increased incidence and mortality rates of cervical cancer in older women [ 8 , 32 ]. Moreover, introduction of immunohistochemistry assessment of biomarkers may aid in the histopathological classification of cervical cancer and other cancers, and may also assist in early identification of Tanzanian women who are at high risk for recurrence of cervical cancer.…”

Section: Discussionmentioning

confidence: 99%

Expression analysis of p16 and TOP2A protein biomarkers in cervical cancer lesions and their correlation with clinico-histopathological characteristics in a referral hospital, Tanzania

et al. 2021

View full text Add to dashboard Cite

Introduction Biomarkers yield important information for early diagnosis of cervical cancer. However, they are rarely applied for prognosis of cervical cancer in Tanzania, where visual inspection assay with acetic acid or Lugol’s iodine and Pap test are being used as the standard screening/ diagnostic methods. Methods This was a retrospective hospital-based cross-sectional study that was conducted to assess cyclin-dependent kinase inhibitor (p16) and topoisomerase II-alpha (TOP2A) proteins expression among women seeking cervical cancer care at Kilimanjaro Christian Medical Centre, Tanzania between May 1, 2017 and May 10, 2018. Immunohistochemistry technique was used to detect the expressions of p16 and TOP2A proteins from the retrieved formalin-fixed and paraffin-embedded (FFPE) cervical biopsies. Results A total of 145 patients, with a mean age of 52.1 ± 12.9 years, were included in this study. Upon immunohistochemistry staining, 103 (71.0%) and 90 (62.1%) were p16 and TOP2A positive respectively. There was a strong association between histopathological class and p16/TOP2A expression levels (Fisher’s exact test, p<0.001). Moreover, there was a strong positive correlation between p16/TOP2A and cancerous cervical lesions (Spearman’s rank correlation coefficients = 0.833 and 0.687, p = 0.006 and 0.005, respectively). The age-adjusted odds ratio for predicting cervical cancer lesions were independently significant for p16/TOP2A biomarkers in FFPE cervical tissues [p16: OR = 1.142 (95% CI: 1.059–1.232, p<0.001) and TOP2A: OR = 1.046 (95% CI: 1.008–1.085, p = 0.015)]. Importantly, the diagnostic performance of p16 was higher than that of TOP2A in the diagnosis of cancerous lesions from non-cancerous cervical lesions (sensitivity: 97.2% versus 77.6%, accuracy: 92.8% versus 87.8%, respectively). Conclusion Our study has highlighted that over-expression of TOP2A is related to the grade of cervical intraepithelial neoplasia but does not predict prognosis in cervical cancer. Similarly, expression of p16 is related to degree of histological dysplasia and malignancy, suggesting its prognostic and predictive value in the management of cervical cancers. Further bigger studies are needed to validate their applications in the early diagnosis of cervical cancer.

show abstract

Incidence, mortality and determinants of survival from cervical cancer in Northwest Russia: a registry-based cohort study

Abstract: Incidence of and mortality from cervical cancer in northwest Russia is considerably higher than in developed countries. Increased incidence in recent years may be attributed to increased screening.

Cited by 12 publications

References 19 publications

Determinants of Mortality among Cervical Cancer Patients Attending in Tikur Anbessa Specialized Hospital, Ethiopia: Institutional-Based Retrospective Study

Determinants of Mortality among Cervical Cancer Patients Attending in Tikur Anbessa Specialized Hospital, Ethiopia: Institutional-Based Retrospective Study

Survival status and associated factors of death among cervical cancer patients attending at Tikur Anbesa Specialized Hospital, Addis Ababa, Ethiopia: a retrospective cohort study

Expression analysis of p16 and TOP2A protein biomarkers in cervical cancer lesions and their correlation with clinico-histopathological characteristics in a referral hospital, Tanzania

Contact Info

Product

Resources

About